Akili Interactive, the Boston company that got the first prescription video game approved last June, has raised another $160 million in funding for its work on digital therapeutics.
Akili plans to use the money partly to expand its marketing of EndeavorRx, a video game approved by the Food and Drug Administration for children with ADHD. The financing round brings the 10-year-old company’s total venture funding to $230 million.
The FDA approved EndeavorRx as a way to improve attention function in children with ADHD as measured by computerized testing. Doctors can prescribe it to kids 8 to 12 years old who have an ADHD diagnosis and have demonstrated an issue with attention.
The latest fund-raising round generated $110 million and was led by Neuberger Berman Funds. More than a dozen other new and existing investors also joined the round, including Amgen Ventures, Polaris Partners and M Ventures, Merck KGaA’s corporate venture capital arm, as well as Dave Baszucki, founder and CEO of video game developer Roblox Corp. Another $50 million was generated through debt financing, in the form of a credit facility with Silicon Valley Bank.
Jonathan Saltzman can be reached at firstname.lastname@example.org.